Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Liver Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Anti CD3 MUC1 bispecific antibody Benhealth Biopharmaceutical (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Benhealth Biopharmaceutical
- 26 Jul 2018 Planned number of patients changed from 60 to 80.
- 26 Jul 2018 Planned End Date changed from 27 Dec 2019 to 31 Dec 2019.
- 26 Jul 2018 Planned primary completion date changed from 31 May 2018 to 31 Dec 2019.